Stock fact sheet · data as of
AIM ImmunoTech Inc. (AIM): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is AIM undervalued?
At 0.1703 (close of 16 Oct 2026), AIM has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -0.83, it pays no dividend and its debts exceed what its assets would fetch), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.
The nightly engine files AIM under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for AIM
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -0.3076 | -281% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
AIM ImmunoTech Inc. scores only 3 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 0.0/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are high - ROIC 285.6%, ROE 142.7%, ROA -241.4% - with debt at -0.50 times equity and negative free cash flow.
AIM ImmunoTech Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Clinical Treatment Programs US 100% (quarter Q4 FY2022).
Institutional ownership scores 1/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | 285.6% |
|---|---|---|---|
| GLS Moat | 0.0 / 10 | ROE | 142.7% |
| Debt / equity | -0.50 | ROA | -241.4% |
| Free-cash-flow yield | -105.4% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 31: No options
No options are listed on AIM ImmunoTech Inc. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 31) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 1.0M shares a day on a market cap of $7M, with a beta of 1.27 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 12 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 13 / 25 | 0% margin of safety | |
| Health | 7 / 20 | Piotroski 3/9 | |
| Moat | 0 / 15 | moat 0.0/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 12 / 20 | 1.0M shares/day, $7M cap, beta 1.27 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 16 Nov 2026 (before the open), 31 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to AIM ImmunoTech Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| SKYE Skye Bioscience, Inc. | 1.57 | 0.7856 | -100% | 3Weak | $7M |
| FBLG FibroBiologics, Inc. Common Stock | 1.00 | 0.7260 | -38% | 14No options | $7M |
| IMRN Immuron Limited | 1.03 | - | - | 30No options | $7M |
| APUS Apimeds Pharmaceuticals US, Inc | 4.39 | - | - | 23No options | $7M |
| ZEOX Zeo ScientifiX, Inc. | 0.9000 | - | - | 31No options | $7M |
| AIMD Ainos, Inc. | 0.9600 | - | - | 19No options | $7M |
| ACXP Acurx Pharmaceuticals, Inc. | 1.17 | 5.07 | +77% | 38No options | $7M |
| CUBT Curative Biotechnology, Inc. | 0.9500 | - | - | 24No options | $6M |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | 0.4782 | 3.09 | +85% | 36Weak | $6M |
| SNGX Soligenix, Inc. | 0.3407 | 1.27 | +73% | 35No options | $7M |
| ENVB Enveric Biosciences, Inc. | 1.39 | 12.40 | +89% | 37No options | $6M |
| NCNA NuCana plc | 1.02 | 14.66 | +93% | 33No options | $6M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about AIM
Is AIM undervalued right now?
The GLS models could not value AIM (the company lost money over the last twelve months, EPS -0.83, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 0.1703 against.
What is the Wheel Score of AIM and what does it mean?
AIM has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for AIM?
None of the nine GLS models produced a positive value for AIM (the company lost money over the last twelve months, EPS -0.83, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.
When does AIM ImmunoTech Inc. report earnings next?
The next earnings report is due on 16 Nov 2026 (before the open), 31 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does AIM have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on AIM, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.